Current Issue | New England Journal of Medicine
Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 8).
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a …
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Dec 11, 2024 · In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or …
The New England Journal of Medicine | Research & Review Articles …
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based …
Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell …
Zongertinib in Previously Treated - The New England Journal of …
Apr 28, 2025 · Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is …
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated ...
Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase …
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy …
Jun 2, 2025 · Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung …
Tirzepatide for Heart Failure with Preserved Ejection Fraction and ...
Nov 16, 2024 · Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and …
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple …
Apr 8, 2025 · Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying …